company background image
460

Sihuan Pharmaceutical Holdings GroupSEHK:460 Stock Report

Last Price

HK$1.59

Market Cap

HK$14.8b

7D

-4.8%

1Y

20.5%

Updated

19 Jan, 2022

Data

Company Financials +
460 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health5/6
Dividends0/6

460 Stock Overview

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China.

Price History & Performance

Summary of all time highs, changes and price drops for Sihuan Pharmaceutical Holdings Group
Historical stock prices
Current Share PriceHK$1.59
52 Week HighHK$3.95
52 Week LowHK$0.92
Beta0.75
1 Month Change20.46%
3 Month Change-6.47%
1 Year Change20.46%
3 Year Change0%
5 Year Change-30.87%
Change since IPO-44.89%

Recent News & Updates

Nov 28
A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Does the November share price for Sihuan Pharmaceutical Holdings Group Ltd. ( HKG:460 ) reflect what it's really worth...

Sep 26
Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

460HK PharmaceuticalsHK Market
7D-4.8%0.1%0.3%
1Y20.5%-20.6%-16.0%

Return vs Industry: 460 exceeded the Hong Kong Pharmaceuticals industry which returned -20.6% over the past year.

Return vs Market: 460 exceeded the Hong Kong Market which returned -16% over the past year.

Price Volatility

Is 460's price volatile compared to industry and market?
460 volatility
460 Average Weekly Movement8.5%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement6.7%
10% most volatile stocks in HK Market13.2%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 460 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 460's weekly volatility has decreased from 16% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20014,223Weicheng Guohttps://www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebral vascular system, digestive system, metabolism, anti-infective, respiratory, neurology, and other drugs. It also engages in the marketing of pharmaceutical products; manufacture of pharmaceutical materials and medical instruments; project preparation for the manufacture of pharmaceutical products; promotion of technology, biotechnology, and consulting services; and construction of medical projects, as well as the provision of information support, research and development, business and development, and general hospital and hospital management services.

Sihuan Pharmaceutical Holdings Group Fundamentals Summary

How do Sihuan Pharmaceutical Holdings Group's earnings and revenue compare to its market cap?
460 fundamental statistics
Market CapCN¥12.10b
Earnings (TTM)CN¥945.30m
Revenue (TTM)CN¥3.32b

12.8x

P/E Ratio

3.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
460 income statement (TTM)
RevenueCN¥3.32b
Cost of RevenueCN¥721.39m
Gross ProfitCN¥2.60b
ExpensesCN¥1.65b
EarningsCN¥945.30m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.10
Gross Margin78.25%
Net Profit Margin28.50%
Debt/Equity Ratio7.6%

How did 460 perform over the long term?

See historical performance and comparison

Valuation

Is Sihuan Pharmaceutical Holdings Group undervalued compared to its fair value and its price relative to the market?

14.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 460 (HK$1.59) is trading below our estimate of fair value (HK$1.87)

Significantly Below Fair Value: 460 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 460 is poor value based on its PE Ratio (12.8x) compared to the Hong Kong Pharmaceuticals industry average (9.8x).

PE vs Market: 460 is poor value based on its PE Ratio (12.8x) compared to the Hong Kong market (9.1x).


Price to Earnings Growth Ratio

PEG Ratio: 460 is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: 460 is overvalued based on its PB Ratio (1.2x) compared to the HK Pharmaceuticals industry average (1.1x).


Future Growth

How is Sihuan Pharmaceutical Holdings Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

22.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 460's forecast earnings growth (22.8% per year) is above the savings rate (1.5%).

Earnings vs Market: 460's earnings (22.8% per year) are forecast to grow faster than the Hong Kong market (16.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 460's revenue (20.5% per year) is forecast to grow faster than the Hong Kong market (11.7% per year).

High Growth Revenue: 460's revenue (20.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 460's Return on Equity is forecast to be low in 3 years time (18.2%).


Past Performance

How has Sihuan Pharmaceutical Holdings Group performed over the past 5 years?

-38.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 460 has a large one-off gain of CN¥217.5M impacting its June 30 2021 financial results.

Growing Profit Margin: 460 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 460's earnings have declined by 38.3% per year over the past 5 years.

Accelerating Growth: 460 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 460 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.8%).


Return on Equity

High ROE: 460's Return on Equity (9.1%) is considered low.


Financial Health

How is Sihuan Pharmaceutical Holdings Group's financial position?


Financial Position Analysis

Short Term Liabilities: 460's short term assets (CN¥7.2B) exceed its short term liabilities (CN¥2.6B).

Long Term Liabilities: 460's short term assets (CN¥7.2B) exceed its long term liabilities (CN¥1.0B).


Debt to Equity History and Analysis

Debt Level: 460 has more cash than its total debt.

Reducing Debt: 460's debt to equity ratio has increased from 0.07% to 7.6% over the past 5 years.

Debt Coverage: 460's debt is well covered by operating cash flow (100.4%).

Interest Coverage: 460 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Sihuan Pharmaceutical Holdings Group current dividend yield, its reliability and sustainability?

4.60%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 460's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 460's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 460's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 460's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 460 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 460's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Weicheng Guo (57 yo)

7.25yrs

Tenure

CN¥6,000,000

Compensation

Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...


CEO Compensation Analysis

Compensation vs Market: Weicheng's total compensation ($USD944.44K) is above average for companies of similar size in the Hong Kong market ($USD480.15K).

Compensation vs Earnings: Weicheng's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 460's management team is seasoned and experienced (7.3 years average tenure).


Board Members

Experienced Board: 460's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sihuan Pharmaceutical Holdings Group Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sihuan Pharmaceutical Holdings Group Ltd.
  • Ticker: 460
  • Exchange: SEHK
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$14.835b
  • Shares outstanding: 9.33b
  • Website: https://www.sihuanpharm.com

Number of Employees


Location

  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Convention Plaza
  • Room 4309, Office Tower
  • Wan Chai
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 15:46
End of Day Share Price2022/01/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.